贝伐珠单抗同步放化疗对脑胶质瘤患者微小RNA、生存结局的影响  

Effects of simultaneous chemoradiotherapy with bevacizumab on micrornas and survival outcomes in patients with glioma

作　　者：殷霞 刘声翊 湛晗 欧阳运洁 高凯波 Yin Xia;Liu Shengyi;Zhan Han;Ouyang Yunjie;Gao Kaibo(Department of Hematology and Oncology,921 Hospital,Joint Logistic Support Force,Chinese People's Liberation Army,Changsha 410003,China)

机构地区：[1]中国人民解放军联勤保障部队第九二一医院血液肿瘤科,湖南410003

出　　处：《脑与神经疾病杂志》2025年第4期224-229,共6页Journal of Brain and Nervous Diseases

基　　金：2022年湖南省教育厅科学研究项目(22C0044)。

摘　　要：目的探究贝伐珠单抗同步放化疗对脑胶质瘤患者微小RNA、生存结局的影响,为改善患者生存结局提供参考。方法选取2018年6月至2021年6月联勤保障部队第九二一医院收治的94例脑胶质瘤患者,按照随机数字表法分为观察组(n=47)、对照组(n=47),对照组给予同步放化疗,观察组给予贝伐珠单抗同步放化疗,比较两组近期疗效、血清肿瘤标志物[血清血管内生长因子(VEGF)、胶质纤维酸性蛋白(GFAP)、表皮生长因子(EGFR)及趋化因子配体-18(CCL-18)]、外周血miR-21、miR-375、免疫功能指标[CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)]、不良反应发生率及生存结局。结果观察组客观缓解率65.96%(31/47)高于对照组44.68%(21/47)(P<0.05),两组疾病控制率比较差异无统计学意义(P>0.05);治疗3个周期及6个周期,观察组血清VEGF、GFAP、EGFR及CCL-18均较对照组低(P<0.05);治疗3个周期及6个周期,观察组外周血miR-21较对照组低,miR-375较对照组高(P<0.05);治疗3个周期及6个周期,观察组外周血CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)较对照组高(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05);两组1年生存率比较差异无统计学意义(P>0.05),观察组2年生存率、中位无进展生存期高于对照组(P<0.05)。结论贝伐珠单抗同步放化疗可提高脑胶质瘤患者临床疗效,调节肿瘤标志物、miR-21、miR-375水平,改善免疫功能,提高生存率。Objective To explore the effects of simultaneous chemoradiotherapy with bevacizumab on micromas and survival outcomes in patients with glioma,and to provide reference for improving survival outcomes.Methods A total of 94 patients with high-grade glioma treated in the 921st Hospital of the Joint Logistics Support Force of the Chinese people's Liberation Army from June 2018 to June 2021 were selected and divided into observation group (n=47)and control group(n=47)according to random number table method.The control group was given synchronous chemoradiotherapy,while the observation group was given simultaneous chemoradiotherapy combined with bevacizumab.The short-term efficacy,serum tumor markers[serum intravascular growth factor(VEGF),glial fibrillary acidic protein(GFAP),epidermal growth factor(EGFR)and chemokine ligand-18(CCL-18)],peripheral blood miR-21,miR-375,and immune function indicators[CD3^(+),CD4^(+),CD4^(+)/CD8^(+)],incidence of toxicity and survival outcomes were compared between the two groups.Results The objective remission rate of the observation group was65.96%(31/47)higher than that of the control group(44.68%,21/47)(P<0.05),and there was no significant difference in disease control rate between the two groups(P>0.05).After 3 and 6 cycles of treatment,VEGF,GFAP,EGFR and CCL-18 in the observation group were lower than those in the control group(P<0.05).After 3 and 6 cycles of treatment,miR-21 in peripheral blood of the observation group was lower than that of the control group,and miR-375was higher than that of the control group(P<0.05).After 3 and 6 cycles of treatment,peripheral blood CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in observation group were higher than those in control group(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).There was no significant difference in 1-year survival between the two groups(P>0.05).The 2-year survival rate and median progression-free survival in the observation group were higher than those in the control

关 键 词：脑胶质瘤 贝伐珠单抗 miR-21、miR-375 肿瘤标志物 生存结局 

分 类 号：R739.4[医药卫生—肿瘤]